Signals, Powered By EquityPandit
On Monday, Glenmark Life Sciences shares had slipped below their issue price of Rs 720 per share on the Bombay Stock Exchange (BSE) in intra-day trade as the stock declined 5 per cent to Rs 713.85. On the other hand, the pharmaceutical company’s supply has dropped 11 per cent from its listing day high of Rs 799.95.
- What is Stock Order : Types, Differences & How Order Works
- India’s Business Activity Hits 3-Month High in Nov Amid Rising Costs
- Trudeau to Cut Sales Tax and Send Checks to Canadians Ahead of Election
- Ashwini Vaishnaw Encourages German Companies to Invest in India
- Flipkart Appoints Dan Bartlett to Board
On August 6 2021, GLS had made a quiet debut on the bourses as the shares listed at Rs 751.10, a 4 per cent premium against the issue price on the BSE.
GLS, a developer and manufacturer of active pharmaceutical ingredients (APIs), is a wholly-owned subsidiary of Glenmark Pharmaceuticals. The company on Friday informed the stock exchanges that the board of directors of the company is scheduled to meet on Friday, August 13, 2021, to consider and approve the company’s unaudited financial results for the first quarter ended June 30, 2021 (Q1FY22).
Stock Covered in the news
